Genomic profiling results from the tumor tissue revealed immunotherapy biomarkers as microsatellite stable with low TMB (5 mut/Mb), mutations in TERT promoter and TP53, amplifications of CDK6, CUL4A, and MET, and equivocal amplifications of FGF14 and IRS2. Here, TP53 is linked to neoplasm.